Rheumatoid Arthritis – Global Drug Forecast and Market Analysis to 2029

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$10995
Buy Report View Sample

Published: December 31, 2020 Report Code: GDHC209PIDR-ST

Select Item

The rheumatoid arthritis (RA) market is expected to grow from $26.2bn in 2019 to $29.1bn in 2029 across the eight major markets (8MM*) at a compound annual growth rate (CAGR) of 1.0%. This report discusses that although the RA market is expected to grow during the forecast period, this growth will be stymied by erosion from biosimilars.

Rose Joachim, PhD, Senior Immunology Analyst at GlobalData, explains: “Between 2019 and 2029, there will be modest growth in the RA market. Growth will mainly be driven by the continued uptake of new marketed products in the Janus kinase (JAK) inhibitor class, as well as the anticipated approval and launch of four pipeline therapies.

GlobalData’s report highlights four late-stage pipeline therapies for RA. Three are biologics, including Taisho’s tumor necrosis factor inhibitor, ozoralizumab, R-Pharm’s interleukin 6 inhibitor, olokizumab, and GlaxoSmithKline’s granulocyte-macrophage colony-stimulating factor inhibitor, otilimab. The fourth drug, Roche/Genentech’s fenebrutinib, is an oral Bruton’s tyrosine kinase inhibitor. Together, these four pipeline agents are expected to represent less than 5% of the RA market in 2029, equivalent to about $1.1bn.

Despite numerous sources of growth and development in the RA market, GlobalData expects market size to be severely impacted by biologic patent expiries, and the subsequent influx of discounted biosimilar products.

Rolling launches of new biosimilars will ratchet up the competition in an already dense, complex market. However, KOLs interviewed by GlobalData have emphasized that despite all the available drugs, there is still room for the standard of care in RA to improve. In particular, they highlighted the need for therapeutic strategies targeting patients with early and preclinical RA, novel pharmaceutical options for treatment-refractory patients, as well as more personalized treatment algorithms for patients with active disease.

*8MM = US, France, Germany, Italy, Spain, the UK, Japan, and Australia; 4EU = France, Germany, Italy, and Spain

Scope

  • Overview of RA including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

  • Topline RA therapeutics market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.

  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting RA therapeutics sales in the 8MM.

  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

  • Analysis of the current and future market competition in the global RA therapeutics market.

  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

The greatest drivers of growth in the global RA market will be the continued uptake of new products in the IL-6 and JAK inhibitor classes, the anticipated approval and launch of four pipeline therapies, a steadily climbing diagnosed prevalence rate, and a high overall treatment rate.

The main barriers to growth in the RA market will be significant market share erosion from biosimilars and tofacitinib generics as well as a challenging environment for new product launches due to intense competition in the market.

KOLs expressed measured enthusiasm for the four pipeline agents in development. Of these agents, KOLs were most interested in the two with new mechanisms of action: GSK’s GM-CSF inhibitor, otilimab, and Roche/Genentech’s BTK inhibitor, fenebrutinib. Although they were dubious that these agents’ efficacy would be comparable to that of JAK inhibitors, they believed they would expand available options for patients and could potentially be useful in future combination regimens.

The most important unmet needs in RA are those for earlier diagnosis and treatment, more cost-effective medications, personalized strategies for treatment of active disease, a better-defined approach to de-escalation of DMARDs during remission, as well as new options for patients with treatment-refractory disease.

Reasons to Buy

The report will enable you to:

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.

  • Develop business strategies by understanding the trends shaping and driving the global RA therapeutics market

  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global RA market in the future.

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

  • Track drug sales in the global RA therapeutics market from 2019-2029.

  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

 

 

KEY QUESTIONS ANSWERED

  • With the increased entry of biosimilars into the RA marketplace, sales growth has begun to slacken and will likely continue to slow over the next 10 years. How will biosimilar uptake differ across the 8MM? What companies and drugs will be most affected by sales erosion from biosimilars?

  • What are the main R&D trends in the RA market and which companies are leading the way?

  • Are there major differences in the mechanisms of action used by therapies in late-stage versus early-stage clinical development?

  • KOLs interviewed by GlobalData have indicated that there are still many remaining unmet needs within the RA indication. What are the main unmet needs in the RA market? How can the pharmaceutical industry address these needs? To what degree will the therapies under development fulfill these unmet needs?

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Rheumatoid Arthritis: Executive Summary

2.1 Biosimilar and Generic Erosion Will Stymie Sales Growth in the RA Market from 2019–2029

2.2 Development of Novel Oral Agents and Biosimilars Are Popular R&D Strategies

2.3 Opportunities Remain for More Rapid, Targeted, and Cost-Effective Treatment for RA Patients

2.4 Late-Stage RA Pipeline Holds Promise But Likely Won’t Match the Utility of JAK Inhibitors

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology

4.2 Pathophysiology

4.2.1 Preclinical RA

4.2.2 Early and Established RA

4.2.3 Therapeutic Mechanisms in RA

4.3 Symptoms and Severity Classifications

5 Epidemiology

5.1 Risk Factors and Comorbidities

5.2 Global and Historical Trends

5.3 Forecast Methodology

5.3.1 Sources

5.3.2 Forecast Assumptions and Methods

5.4 Epidemiological Forecast for RA (2019–2029)

5.4.1 Diagnosed Incident Cases of RA

5.4.2 Sex-Specific Diagnosed Incident Cases of RA

5.4.3 Age-Specific Diagnosed Incident Cases of RA

5.4.4 Diagnosed Prevalent Cases of RA

5.4.5 Sex-Specific Diagnosed Prevalent Cases of RA

5.4.6 Age-Specific Diagnosed Prevalent Cases of RA

5.4.7 Diagnosed Prevalent Cases of RA by Severity

5.4.8 Total Prevalent Cases of RA

5.4.9 Sex-Specific Total Prevalent Cases of RA

5.4.10 Age-Specific Total Prevalent Cases of RA

5.4.11 Total Prevalent Cases of RA by Severity

5.5 Discussion

5.5.1 Epidemiological Forecast Insight

5.5.2 Limitations of the Analysis

5.5.3 Strengths of the Analysis

6 Disease Management

6.1 Diagnosis and Treatment Overview

6.1.1 Diagnosis

6.1.2 Treatment

6.2 US

6.3 5EU

6.4 Japan

6.5 Australia

7 Competitive Assessment

7.1 Overview

7.2 Biosimilars in the RA Market

7.2.1 Marketed Biosimilars

7.2.2 Pipeline Biosimilars

7.2.3 Pricing of Biosimilars across the 8MM

7.2.4 Uptake of Biosimilars across the 8MM

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Earlier Diagnosis and Treatment

8.2.1 Improved Access to Rheumatologists

8.2.2 Diagnosis and Treatment of Early, Undifferentiated, and Preclinical RA

8.3 Cost-Effective Therapies

8.3.1 Biosimilars

8.3.2 Tofacitinib Generics

8.4 Personalized Treatment Strategies

8.5 Improved Guidance on Treating RA Patients in Remission

8.6 New Treatment Options for Patients with Refractory RA

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

9.2.1 TNF Inhibitors

9.2.2 IL-6 Inhibitors

9.2.3 GM-CSF Inhibitors

9.2.4 Kinase Inhibitors

9.3 Other Drugs in Development – Kinase Inhibitors

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Company Portfolio Assessments

10.3.1 AbbVie

10.3.2 Pfizer

10.3.3 Amgen

10.3.4 Johnson & Johnson

10.3.5 Bristol-Myers Squibb

10.3.6 Roche/Genentech

10.3.7 Eli Lilly

10.3.8 UCB

10.3.9 Sanofi

10.3.10 Regeneron

10.3.11 Astellas

10.3.12 Gilead

10.3.13 Galapagos

10.3.14 GSK

10.3.15 R-Pharm

10.3.16 Taisho

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

11.5 Australia

11.5.1 Forecast

11.5.2 Key Events

11.5.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Diagnosed Patients

12.3.3 Percent Drug-Treated Patients

12.3.4 Drugs Included in Each Therapeutic Class

12.3.5 Launch and Patent Expiry Dates

12.3.6 General Pricing Assumptions

12.3.7 Individual Drug Assumptions

12.3.8 Generic/Biosimilar Erosion

12.3.9 Pricing of Pipeline and Recently Approved Agents

12.4 Primary Research – KOLs and Payers Interviewed for This Report

12.4.1 KOLs

12.4.2 Payers

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Therapy Area Director

12.6.3 Epidemiologist

12.6.4 Epidemiology Reviewers

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

Table

Table 1: RA: Key Metrics in the 8MM

Table 2: RA Disease Severity Classification

Table 2: Risk Factors and Comorbidities for RA

Table 4: Classification Criteria for RA – ACR 1987

Table 5: Classification Criteria for RA – ACR/EULAR 2010

Table 6: Treatment Guidelines for RA, 2020

Table 7: ACR/EULAR Diagnostic Definitions of Remission in RA Clinical Trials

Table 8: Country Profile – US

Table 9: Regional Profile – 5EU

Table 10: Country Profile – Japan

Table 11: Country Profile – Australia

Table 12: Leading Branded Treatments for RA, 2020

Table 13: Marketed Biosimilars for RA, 2020

Table 14: Expected Adalimumab Biosimilar Launches in the US

Table 15: Pipeline Biosimilars for RA, 2020

Table 16: Average Percent Discount on Biosimilars Compared to Biologic Reference Products Across the 8MM, 2020

Table 17: AbbVie’s RA Portfolio Assessment, 2020

Table 18: Pfizer’s RA Portfolio Assessment, 2020

Table 19: Amgen’s RA Portfolio Assessment, 2020

Table 20: J&J’s RA Portfolio Assessment, 2020

Table 21: BMS’ RA Portfolio Assessment, 2020

Table 22: Roche/Genentech’s RA Portfolio Assessment, 2020

Table 23: Eli Lilly’s RA Portfolio Assessment, 2020

Table 24: UCB’s RA Portfolio Assessment, 2020

Table 25: Sanofi’s RA Portfolio Assessment, 2020

Table 26: Regeneron’s RA Portfolio Assessment, 2020

Table 27: Astellas’ RA Portfolio Assessment, 2020

Table 28: Gilead’s RA Portfolio Assessment, 2020

Table 29: Galapagos’ RA Portfolio Assessment, 2020

Table 30: GSK’s RA Portfolio Assessment, 2020

Table 31: R-Pharm’s RA Portfolio Assessment, 2020

Table 32: Taisho’s RA Portfolio Assessment, 2020

Table 33: RA Market – Global Drivers and Barriers, 2019–2029

Table 34: Key Events Impacting Sales for RA in the US, 2019–2029

Table 35: RA Market – Drivers and Barriers in the US, 2019–2029

Table 36: Key Events Impacting Sales for RA in the 5EU, 2019–2029

Table 37: RA Market – Drivers and Barriers in the 5EU, 2019–2029

Table 38: Key Events Impacting Sales for RA in Japan, 2019–2029

Table 39: RA Market – Global Drivers and Barriers in Japan, 2019–2029

Table 40: Key Events Impacting Sales for RA in Australia, 2019–2029

Table 41: RA Market – Global Drivers and Barriers in Australia, 2019–2029

Table 42: Key Historical and Projected Launch Dates for RA

Table 43: Key Historical and Projected Patent/Exclusivity Expiry Dates for RA

Table 44: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figures

Figure 1: Global Sales Forecast by Country for RA in 2019 and 2029

Figure 2: Analysis of the Company Portfolio Gap in RA During the Forecast Period, 2019–2029

Figure 3: Competitive Assessment of Recently Approved and Late-Stage Pipeline Agents for the Treatment of RA During the Forecast Period, 2019–2029

Figure 4: Overview of RA Pathogenesis and Pathophysiology

Figure 5: Cellular and Cytokine Targets for the Marketed and Late-Stage Pipeline RA Drugs, 2020

Figure 3: 8MM, Diagnosed Incidence of RA (Cases per 100,000 Population), Both Sexes, Ages ≥18 Years, 2019

Figure 4: 8MM, Diagnosed Prevalence (%) of RA, Both Sexes, Ages ≥18 Years, 2019

Figure 5: 8MM, Total Prevalence (%) of RA, Both Sexes, Ages ≥18 Years, 2019

Figure 6: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of RA

Figure 7: 8MM, Sources Used and Not Used to Forecast the Diagnosed and Total Prevalent Cases of RA

Figure 8: 8MM, Diagnosed Incident Cases of RA, N, Both Sexes, Ages ≥18 Years, 2019

Figure 9: 8MM, Diagnosed Incident Cases of RA, N, by Sex, Ages ≥18 Years, 2019

Figure 10: 8MM, Diagnosed Incident Cases of RA by Age, N, Both Sexes, 2019

Figure 11: 8MM, Diagnosed Prevalent Cases of RA, N, Both Sexes, Ages ≥18 Years, 2019

Figure 12: 8MM, Diagnosed Prevalent Cases of RA, N, by Sex, Ages ≥18 Years, 2019

Figure 13: 8MM, Diagnosed Prevalent Cases of RA by Age, N, Both Sexes, 2019

Figure 14: 8MM, Diagnosed Prevalent Cases of RA by Severity, N, Both Sexes, Ages ≥18 Years, 2019

Figure 15: 8MM, Total Prevalent Cases of RA, N, Both Sexes, Ages ≥18 Years, 2019

Figure 16: 8MM, Total Prevalent Cases of RA, N, by Sex, Ages ≥18 Years, 2019

Figure 17: 8MM, Total Prevalent Cases of RA by Age, N, Both Sexes, 2019

Figure 18: 8MM, Total Prevalent Cases of RA by Severity, N, Both Sexes, Ages ≥18 Years, 2019

Figure 22: General Treatment Algorithm for RA Patients, 2020

Figure 23: 8MM Physician-Reported Biosimilar Prescription Rates to RA Patients, 2020

Figure 24: 5EU Physician-Reported Biosimilar Prescription Rates to RA Patients, 2020

Figure 25: Unmet Needs and Opportunities in RA, 2020

Figure 26: Overview of the Development Pipeline in RA

Figure 27: Key Phase II/III Trials for the Promising Pipeline Agents That GlobalData Expects to Be Licensed for RA in the 8MM During the Forecast Period, 2019–2029

Figure 28: Competitive Assessment of Recently Approved and Late-Stage Pipeline Agents for the Treatment of RA During the Forecast Period, 2019–2029

Figure 29: Analysis of the Company Portfolio Gap in RA During the Forecast Period, 2019–2029

Figure 30: Global (8MM) Sales Forecast by Country for RA in 2019 and 2029

Figure 31: Global (8MM) Sales Forecast for RA, by Class, in 2019 and 2029

Figure 32: Sales Forecast by Class for RA in the US in 2019 and 2029

Figure 33: Sales Forecast by Class for RA in the 5EU in 2019 and 2029

Figure 34: Sales Forecast by Class for RA in Japan in 2019 and 2029

Figure 35: Sales Forecast by Class for RA in Australia in 2019 and 2029

Frequently asked questions

Rheumatoid Arthritis – Global Drug Forecast and Market Analysis to 2029 standard reports
Currency USD
$10,995

Can be used by individual purchaser only

Most Popular
$21,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Rheumatoid Arthritis – Global Drug Forecast and Market Analysis to 2029 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Immunology reports
Pharmaceuticals
New
Bronchiectasis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and…
$6,995 | May 2024
Pharmaceuticals
New
Pharma M&A Deals Q1 2024 - Top Themes - Thematic…
$995 | May 2024
Pharmaceuticals
New
HER2-Positive Breast Cancer Epidemiology Analysis and Forecast to 2033
$3,995 | May 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Rheumatoid Arthritis – Global Drug Forecast and Market Analysis to 2029 in real time.

  • Access a live Rheumatoid Arthritis – Global Drug Forecast and Market Analysis to 2029 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more